source
- STAT+: Beyond statins, one drug lowered heart attack risk by 20%A new study could help doctors figure out what medicine to prescribe for cholesterol when statins don't cut it: It's “answering a really challenging clinical question."
- Vivoryon reclaims Chinese rights to kidney disease drug amid cash crunchVivoryon Therapeutics, a Munich-based biotech, has taken back the rights to develop its kidney disease candidate in China after a licensing arrangement with Simcere Pharmaceuticals. The original 2…